

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA PIONEER PHARMA HOLDINGS LIMITED**

**中国先锋医药控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01345)**

### **ANNOUNCEMENT SUPPLEMENTAL AGREEMENT TO THE LOAN AGREEMENT WITH Q3 MEDICAL DEVICES LIMITED**

We refer to the announcement (the “**Announcement**”) of China Pioneer Pharma Holdings Limited (the “**Company**”) dated 31 December 2013 relating to the Loan Agreement entered into between the Company and Q3 in relation to, among other things, the confirmation of Q3 not to make a request to Pioneer Singapore for Convertible Loan 3 or to act as the Guarantor, and, instead, the granting of a loan of EUR 1,500,000 by Pioneer Singapore to Q3 (the “**Loan**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

Pursuant to the Loan Agreement dated 31 December 2013, Pioneer Singapore and Q3 would negotiate in good faith, reflecting market conditions, such further terms as may be required with regard to the payment of interest by Q3 to Pioneer Singapore in respect of the Loan and the rate thereof.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that, on 14 January 2014, the Company and Q3 entered into a supplemental agreement to the Loan Agreement (the “**Supplemental Agreement**”) fixing the interest rate of the Loan at 10% (ten percent) per annum, which will accrue on the principal amount of the Loan from day to day and shall be paid by Q3 to the Company upon repayment of the Loan.

The Company believes that the interest rate as agreed upon in the Supplemental Agreement reflects market conditions. The Directors are of the view that the terms and conditions of the Loan Agreement as modified by the Supplemental Agreement and the transaction contemplated therein are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

**Shareholders and potential investors should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China Pioneer Pharma Holdings Limited**  
**Li Xinzhou**  
*Chairman*

Hong Kong, 14 January 2014

*As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. ZHU Mengjun as executive Directors, Mr. LU Yuan, Mr. WU Mijia and Mr. ZHANG Wenbin as non-executive Directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.*